Hatch Takes Aim At Kennedy’s Commissioner Criteria, Supports Crawford
This article was originally published in The Gray Sheet
Executive Summary
Ties to an FDA-regulated industry should not preclude a candidate's nomination to the agency's top position, Sen. Orrin Hatch (R-Utah) asserted April 16 at the Food & Drug Law Institute Educational Conference in Washington, D.C
You may also be interested in...
Kerry Could Look To Kessler To Help Tap FDA Head; Wood A Possibility?
Former FDA Commissioner David Kessler may figure prominently in the selection of a new commissioner in the event that a Kerry Administration takes over the White House in November
Kerry Could Look To Kessler To Help Tap FDA Head; Wood A Possibility?
Former FDA Commissioner David Kessler may figure prominently in the selection of a new commissioner in the event that a Kerry Administration takes over the White House in November
FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
The growing call for greater federal cost-effectiveness evaluation of new medical technologies will not alter FDA's primary focus on risk-benefit analysis